To examine the impact of overweight and obesity on development of target organ damage in the early stage of hypertension. SUBJECTS: Participants were 727 young-to-middle-age subjects screened for stage 1 hypertension and followed for 8 years. MEASUREMENTS: Ambulatory blood pressure (BP), albumin excretion rate and echocardiographic data were obtained at entry, every 5 years and/or before starting antihypertensive treatment. RESULTS: During the follow-up, hypertension needing treatment was developed by 54.7% of the subjects with normal weight, 66.6% of those with overweight and 73.0% of those with obesity (Po0.001). Kaplan --Meier curves showed that patients with obesity or overweight progressed to sustained hypertension earlier than those with normal weight (Po0.001). At study end, rate of organ damage was 10.7% in the normal weight, 16.4% in the overweight and 30.1% in the obese subjects (Po0.001). In a multivariable logistic regression analysis, overweight (P ¼ 0.008) and obesity (Po0.001) were significant predictors of final organ damage. Inclusion of changes in 24-h BP and body mass index, and of baseline organ damage did not virtually modify these associations (P ¼ 0.002 and o0.001, respectively). Obesity was a significant predictor of both left ventricular hypertrophy (Po0.001) and microalbuminuria (P ¼ 0.015) with an odds ratio (95% confidence interval) of 8.5 (2.7 --26.8) and 3.5 (1.3 --9.6), respectively. CONCLUSION: These data indicate that in hypertensive subjects obesity has deleterious effects on the cardiovascular system already at an early age. Preventive strategies addressed to achieve weight reduction should be implemented at a very early stage in young people with excess adiposity and high BP. 1,2 A strong clinical association has been reported between Ov --Ob and hypertension, both in cross-sectional and longitudinal studies.
INTRODUCTION
Overweight and obesity (Ov --Ob) and obesity-related hypertension are increasing worldwide together with their cardiovascular complications.
1,2 A strong clinical association has been reported between Ov --Ob and hypertension, both in cross-sectional and longitudinal studies. 3, 4 However, whether the coexistence of Ov --Ob and hypertension implies an additional increase in cardiovascular risk, as opposed to the presence of only one of these conditions, is still unclear. Cross-sectional studies indicate that target organ damage (TOD) is more common in obese than nonobese hypertensives, suggesting that TOD occurring in obesity may be partly independent of blood pressure (BP) load. 5, 6 However, the clinical factors and pathogenetic mechanisms underlying TOD deterioration in obese versus nonobese hypertensive subjects have not yet been clearly elucidated, especially in the younger segment of the hypertensive population. Because of the paucity of data in published reports, we examined the risk of hypertension needing drug treatment, of microalbuminuria and left ventricular hypertrophy (LVH) in a cohort of young-to-middleage subjects screened for stage 1 hypertension. The aim of this study was to ascertain whether subjects with Ov --Ob in the initial stage of hypertension have a worse prognosis in comparison with subjects with normal weight (NW). Another purpose was to ascertain whether the associations of Ov --Ob with outcome variables were affected by changes in ambulatory BP and body mass index (BMI) over time.
MATERIALS/SUBJECTS AND METHODS

Study subjects
This analysis was carried out in 727 white subjects taking part in the HARVEST (Hypertension and Ambulatory Recording VEnetia STudy) who had 24-h ambulatory BP recordings and data on TOD at the baseline and at the end of the follow-up. 7 --9 Subjects with baseline diastolic clinic BP between 90 and 99 mm Hg and/or systolic BP between 140 and 159 mm Hg at initial screening were enrolled. None of the subjects had received any antihypertensive treatment before the study. Patients with diabetes mellitus, nephropathy and cardiovascular disease were excluded. The rationale for excluding patients with these comorbidities was prompted by the necessity of keeping our participants untreated for a sufficiently long period of time to study the natural evolution of TOD without intervention. Consecutive patients with the above-mentioned clinical characteristics seen in the offices of the general practitioners and willing to participate in the study were eligible for recruitment and were sent to 17 referral Centers in North-East Italy. The higher prevalence of men among our study participants (72%) confirms previous observations of a much higher prevalence of men in the young segment of the hypertensive population. 10 At the baseline, all subjects underwent physical examination, anthropometry, blood and urine sampling, office BP and 24-h BP measurements, electrocardiogram, echocardiography, and 24-h urinary albumin measurement. BMI was used as an index of obesity (weight divided by height squared). Subjects were defined as NW if their BMI was o25 kg m
À2
, overweight if their BMI was X25 and o30 kg m À2 and obese if their BMI was X30 kg m À2 . Fasting serum glucose, total and high-density lipoprotein cholesterol and triglycerides were measured with standard techniques. The data included a medical and family history and a questionnaire of current use of alcoholic beverages and tobacco and physical activity habits. 7 The study was approved by the Ethics Committee of the University of Padova, and written informed consent was given by the participants. The procedures followed were in accordance with institutional guidelines.
Blood pressure measurement
The mean of six readings taken during two separate visits was defined as baseline clinic BP. Phase V Korotkoff sound was considered as diastolic BP, except for subjects with sounds tending to zero, in whom phase IV was taken. A 24-h BP monitoring was performed with A&D TM2420 model 7 (A&D Co., Tokyo, Japan) or ICR Spacelabs 90207 monitor (Spacelabs Inc., Redmond, WA, USA). Both devices were validated previously. 7 The arithmetic average of the 24-h BP period was used as the ambulatory measurement. Other details on the ambulatory monitoring procedure were reported elsewhere. 7 Twenty-four-hour urine collection During the 24-h recordings, urine was collected for albumin excretion rate (AER), epinephrine and norepinephrine measurement. Immediately after completion, volumes were measured and urine specimens were frozen (À20 1C) and sent to the Coordinating Office in Padova. 9 Here the urinary albumin level was measured by a commercially available radioimmunoassay kit (H ALB kit-double antibody; Sclavo SpA, Cinisello Balsamo, Italy). The lower limit of detection of this technique is an albumin concentration of 0.5 mg l
À1
. The intra-and inter-assay variabilities of the method in our laboratory were 4.4% and 6%, respectively. 9 Valid data on AER at baseline and follow-up end were available in 626 subjects and were expressed as mg per 24 h. Microalbuminuria (AER X30 mg per 24 h) detected in two consecutive measurements was used as the outcome variable. In 486 participants, epinephrine and norepinephrine were assessed by a highperformance liquid chromatography method and normalized for urinary creatinine. Results were expressed as mg g À1 . Urine specimens were frozen (À20 1C) and sent to the Coordinating Office at the University of Padova, where they were processed. 7 AER and catecholamine data were transformed logarithmically to correct for skewing in distribution.
Echocardiography
Echocardiography at the baseline and at the end of the study was obtained in 573 subjects. In 489 of them M-mode images were technically satisfactory and were used for analysis. All measurements were made blind by two observers according to the American Society of Echocardiography at the Coordinating Center at the University of Padova laboratory. 7 Three consecutive beats obtained during quiet respiration were measured and averaged. Left ventricular internal diameter was measured at end diastole, according to the American Society of Echocardiography. 11 Left ventricular mass (LVM) was calculated according to the following formula: 12 where IVS is interventricular septum thickness in diastole; PWT is posterior wall thickness in diastole; and LVDD is left ventricular diameter in diastole. LVM was indexed by height (LVMI) to the allometric power of 2.7. 13 LVH was defined as a LVMI X50 g m À2.7 in men and 47 g m À2.7 in women. 13 Relative wall thickness was defined as the ratio of wall thickness to end diameter in diastole. Data on reproducibility of echocardiographic measurements in our sample have been reported previously. 14 
Follow-up
In the HARVEST study, office BP and lifestyle habits are assessed monthly during the first 3 months of follow-up, then after 6 months and every 6 months thereafter. As HARVEST is not an intervention study, after baseline examination subjects are given general information about nonpharmacological measures by the investigators, following the suggestions of current guidelines on the management of hypertensive patients, 7 --9 but no specific individualized program is offered to them. Ob --Ov subjects are advised to change their body weight to the ideal range. 15 To ensure homogeneous counseling by doctors participating in the study, training in current international guidelines was provided to them throughout the study duration. HARVEST participants are followed until they develop sustained hypertension requiring antihypertensive treatment according to the guidelines available at the time.
7 --9 Ambulatory BP monitoring is performed at the baseline, after 3 months, 5 years, 10 years or just before starting antihypertensive treatment in the patients who needed drug treatment. Patients who develop sustained hypertension needing antihypertensive medication receive the final 24-h BP and TOD assessment before starting therapy. In the patients who remained untreated, the last available BP monitoring, urinary albumin measurement and echocardiographic data were used to calculate final ambulatory BP, microalbuminuria and LVH, respectively. Median follow-up for the 727 participants was 8.0 years (interquartile range, 4.9 --11.0 years). Other details on follow-up procedures were reported elsewhere. 7 --9 Data analysis Data are presented as mean±s.d., unless specified. Between-group differences were assessed with the analysis of variance test for the variables normally distributed. Data were adjusted for age and sex by the use of linear regression analysis. Follow-up changes in clinical variables were evaluated using a general linear model, with the value for the measurement of interest serving as the dependent variable and gender, age, time to final assessment and baseline data serving as independent variables. The significance of differences in categorical variables was assessed with the w 2 test. Time-dependent Cox proportional-hazards analysis were used to regress time until development of hypertension needing treatment against BMI category adjusting for age and sex. To study the association between BMI category and measures of TOD, logistic regression analysis was used because AER and LVMI were measured at fixed preset 5-year intervals. 16 Regression results were presented as odds ratios (ORs) and their respective 95% confidence intervals. Other variables included in the models were sex, age, ambulatory systolic and diastolic BPs, ambulatory heart rate, parental hypertension, smoking status, alcohol consumption, physical activity, changes in ambulatory BPs over time, changes in BMI, and baseline AER (for microalbuminuria), baseline LVMI (for LVH) or baseline TOD (for TOD). A two-tailed probability value o0.05 was considered significant. All analyses were performed using Statistica version 6 (Stat Soft Inc., Tulsa, OK, USA) and Systat versions 10 and 11 (SPSS Inc., Evanston, IL, USA).
RESULTS
The clinical characteristics of the study subjects are reported in Table 1 . At baseline, 49.9% of the subjects had Ov --Ob (overweight, 39.8%; obesity, 10.2%). Ov --Ob subjects were older, were more frequently male and drank more coffee than NW subjects. Alcohol use was more common among the subjects with overweight and sedentariety among those with obesity. Total cholesterol and triglycerides progressively increased with increasing BMI, whereas high-density lipoprotein cholesterol progressively decreased. No significant differences were found for fasting glucose. Clinic and ambulatory diastolic BPs progressively increased on going from the NW to the obese subjects. Urinary norepinephrine was higher among the obese subjects than the other BMI categories (Figure 1) . No difference in epinephrine emerged between the three groups.
Follow-up changes in BP and BMI Small changes in clinic systolic and diastolic BP were observed during the 8 years of follow-up without significant differences between the groups (Table 2) . Ambulatory systolic and diastolic BP slightly increased in all groups, but the between-group differences were not significant. Changes in BMI were inversely proportional to initial BMI. A BMI increase was observed in the NW individuals, a smaller increase in the overweight subjects and a slight decline in the obese participants (P for analysis of covariance o0.001). After adjustment for baseline BMI, the between-group differences were no longer significant. Parallelly, favorable changes in total cholesterol (P ¼ 0.056) and triglycerides (P ¼ 0.038) were observed in the obese subjects compared with the NW individuals ( Table 2) .
During the follow-up, 61.3% of the participants developed hypertension needing antihypertensive treatment according to current guidelines. The rate of hypertension progressively increased across the BMI categories being 54.7% in the NW, 66.6% in the overweight and 73.0% in the obese subjects (Po0.001). The Kaplan --Meier estimated curves of probability of developing sustained hypertension according to BMI group showed that the patients with obesity or overweight progressed to sustained hypertension earlier than those with NW (log rank Po0.001) (Figure 2 ). After taking into account sex and age, a Cox proportional hazards analysis assessing the risk of hypertension showed that Ob --Ov was a significant predictor of incident hypertension (P ¼ 0.005).
End-organ damage at follow-up end Of the 727 participants, 109 had microalbuminuria and/or LVH at the final examination. TOD was more common in the subjects who developed hypertension (22.0%) than in those who remained normotensive (4.3%, Po0.001 versus hypertensives). TOD was 10.7% in the NW subjects, 16.4% in the overweight individuals and 30.1% in the obese subjects (Po0.001). In both normotensive and hypertensive groups at final examination, TOD increased across BMI categories. In a multivariable logistic analysis both overweight (P ¼ 0.008) and obesity (Po0.001) were significant predictors of final TOD. Inclusion of changes in 24-h BP (P ¼ 0.001 and o0.001, respectively), changes in BMI (P ¼ 0.001 and o0.001, respectively) and baseline TOD (P ¼ 0.002 and o0.001, respectively) did not virtually modify these associations. Also when hypertensive status at study end (yes/no) was taken into account, the association of Ov --Ob with TOD remained unchanged (P ¼ 0.002 and o0.001, respectively).
Microalbuminuria at follow-up end was present in 8.2% of the participants and was more common in the obese subjects than the other two groups (Figure 3) . In a multivariable logistic regression model, obesity was a significant predictor of final microalbuminuria (Table 3 ). This association did not virtually change when follow-up changes in 24-h BP and changes in BMI were incorporated in the model and when baseline AER was also included. At variance, overweight was not a significant predictor of final microalbuminuria in any model.
The rate of LVH at follow-up end (14.4%) progressively increased on going from the NW to the obese subjects (Figure 3) . In a multivariable logistic model, both Ov --Ob were significant predictors of final LVH (Table 4 ). This association remained highly significant also when follow-up changes in 24-h BP and BMI and baseline LVMI were incorporated in the model.
DISCUSSION
Our results show that young-to-middle-age Ov --Ob subjects are at increased risk of developing hypertensive TOD compared with NW subjects after adjustment for other risk factors and possible confounders. The risk of hypertension and TOD progressively Data are means and 95% confidence interval (CI), and are adjusted for age and sex. 0 ¼ normal-weight subjects, n ¼ 229; 1 ¼ overweight subjects, n ¼ 200; and 2 ¼ obese subjects, n ¼ 57.
increased with increasing BMI and this association was independent of changes in BMI and 24-h BP during the follow-up. Among the obese subjects, the risk of LVH was 8.5 greater than among the NW subjects, and the risk of microalbuminuria was 3.5 greater. These findings were obtained in a cohort of untreated randomly selected non-diabetic population of subjects screened for stage 1 hypertension, thus avoiding the confounding effect of antihypertensive treatment on progression of TOD.
LVH and microalbuminuria are frequent complications of hypertension and are important risk factors for cardiovascular diseases. 17 --20 Our longitudinal data confirm previous crosssectional studies in adolescents that showed that LVH is more frequent in subjects with both hypertension and elevated BMI than in subjects with either condition alone. 21, 22 In the literature, there is no agreement on BMI-related differences in development of microalbuminuria in patients with hypertension. 23 In fact, some cross-sectional studies reported a direct association between BMI and urinary albumin excretion, 5 whereas others failed to observe any significant relationship between these variables. 24 The present longitudinal results show that in non-diabetic obese hypertensives o45 years subclinical kidney damage develops more frequently than in NW hypertensive subjects.
The pathogenetic mechanisms leading to a greater rate of hypertensive complications in Ov --Ob patients are not completely understood. In this study, hypertension needing treatment developed more frequently in Ov --Ob subjects than in NW individuals and thus part of the association of Ov --Ob with TOD may be attributed to a hemodynamic effect. However, the relationship between Ov --Ob with TOD remained highly significant also when 24 h BP at baseline and changes in 24 h BP or incidence of hypertension during follow-up were included in the logistic models. This suggests that Ov --Ob is also a nonhemodynamic determinant of TOD. However, it should be noted that in all groups 8-year changes in ambulatory BP were rather small (o5 mm Hg) and that larger changes could have had a different effect on TOD. The same comment applies to the effect of follow-up changes in BMI, which affected the relationship between baseline BMI and TOD only marginally, but were generally of small magnitude. End organ deterioration associated with obesity may be due to a poorer metabolic profile. Our Ov --Ob subjects had higher cholesterol and triglycerides and lower highdensity lipoprotein cholesterol than NW individuals and it is known that lipid abnormalities are independent determinant of LVH. 25 In keeping with previous reports, 26 our obese participants had increased level of norepinephrine compared with their lean counterparts. Previous results indicate a possible role for the sympathetic nervous system in cardiac remodeling in obesity, even in the absence of hypertension. 27 Lambert et al. 28 found a direct relationship between LVM and muscle sympathetic nervous activity in young normotensive individuals with excess weight, similar to that observed in hypertensive subjects. A study in young adults showed that high insulin coupled with increased sympathetic activity was a major determinant of left ventricular wall growth and remodeling. 29 Other factors commonly present with excess adiposity, such as activation of the renin --angiotensin system, leptin, inflammatory cytokines and adipokines may contribute to or act in concert with the sympathetic nervous system to initiate end-organ dysfunction in young Ov --Ob subjects. 28, 29 A better understanding of the role of the sympathetic nervous system in obesity-associated hypertension could provide a rational background for more effective treatment and better prevention of hypertensive complications. According to some authors, increased sympathetic tone may be a common pathogenetic mechanism for hypertension, obesity and TOD development. 28, 30 This would explain why deterioration of target organs in our obese individuals occurred in spite of favorable changes in BMI and lipid profile, in comparison with their NW counterparts. However, it should be noted that mean reduction in BMI after 8 years as an effect of medical counseling about lifestyle modifications was small, suggesting that treatment of obesity in hypertension should be pursued more vigorously using individualized programs.
Limitations
Several limitations of this study should be acknowledged and discussed. First, we do not have evidence that the Ov --Ob subjects were counseled more vigorously as compared with NW subjects and cannot exclude that the inverse relationship between baseline BMI and BMI changes during follow-up are at least partially due to regression to the mean. However, the inclusion of a control group (that is, obese people not given medical advice) would have been ethically questionable. Second, we studied a higher proportion of men compared with women. However, this was the direct consequence of the screening procedure and was an expected result for people in that age range. Finally, reporting OR as a measure of association may have magnified the role of obesity as a risk factor for TOD. OR may overstate the effect size when events are common and the distortion is especially large when the event rate is high in only one group. 31 However, its association with the relative risk has long made it valuable for characterizing population variations in risk and this method is currently used to target prevention or screening strategies. 32 On the contrary, a strength of this study is that BP was assessed also with the use of ambulatory monitoring, which is known to predict TOD better than office BP, both at the beginning and at the end of the study.
CONCLUSION
Previous research has shown that obesity-related relative risk of death from cardiovascular diseases is higher in younger than in older subjects. 33, 34 These data support the concept that obesity has deleterious effects on the cardiovascular system already at an early age, well before clinical manifestations of cardiovascular disease become apparent, and indicate that the impact of excess adiposity on TOD is particularly detrimental in hypertensive subjects. Non-pharmacological measures, such as diet-induced weight loss and increased physical activity, are the cornerstones of the treatment of obesity and the associated high BP. These results indicate that preventive strategies addressed to achieve BMI reduction should be implemented at a very early stage in young people with increased BMI and high-normal BP before hypertension and TOD develop. Whether intervention aiming at decreasing sympathetic activity in these subjects would also confer beneficial effects remains to be established. 
